Regarding the use of granulocyte-colony stimulating factors (G-CSF), 5 days of short-acting G-CSF is sufficient to prevent febrile neutropenia or treatment-related hospitalization (REaCT-G & G2) [32,33]. Here, CSF3 is linked to neutropenia.